Loading...
NPI 1538156732 · Elgin, IL · Hematology & Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Syed Zahir is a hematology & oncology physician provider located in Elgin, Illinois. This profile covers 61 Medicare and 13 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Syed Zahir |
| Address | 1710 N. Randall Rd |
| City | Elgin |
| State | IL |
| ZIP | 60123 |
| Taxonomy | Hematology & Oncology Physician |
| NPI Enumerated | October 3, 2005 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $3.1M |
| Medicaid | $72.4K |
This provider’s business is overwhelmingly Medicare-facing: total Medicare revenue is $3.1M compared with total Medicaid revenue of $72.4K, so Medicare represents the vast majority of billed revenue. Medicaid appears to be a minor payer for this NPI in scale, making the organization effectively Medicare-centric for revenue planning and contract negotiations.
Revenue concentration on Medicare is high: the precomputed top three Medicare codes (J9145, J9047, J1568) account for 56.8% of the provider’s Medicare revenue. Those three codes include J9145 ($1M, 34.0% of Medicare revenue), J9047 ($424.8K, 14.0%), and J1568 ($266K, 8.8%), indicating a few therapeutics drive more than half of Medicare billings.
The Medicare code mix identifies a specialty infusion/oncology operation: high-revenue drug codes (J9145 daratumumab, J9047 carfilzomib, J9312/J5119 rituximab biosimilar) plus chemotherapy administration and infusion codes (96413, 96365, 96375, 96415) point to routine clinic-based administration of high-cost oncology biologics and systemic chemotherapy. Supportive-care drugs (J1568 immune globulin, J0881 darbepoetin alfa, J2506 pegfilgrastim) further underscore a full-spectrum hematology/oncology infusion service rather than a pure office-only practice.
Medicaid billing is concentrated in evaluation & management: the top three Medicaid codes (99214, 99213, 99232) account for 93.1% of the provider’s Medicaid revenue, with 99214 at $46.4K (64.0%), 99213 at $15.5K (21.4%), and 99232 at $5.6K (7.7%). This pattern indicates Medicaid revenue is driven by office and hospital E/M visits rather than by high-cost drug administration under Medicaid for this NPI.
Several codes are statistical outliers on Medicare and signal unusually high throughput for selected services. Office E/M codes 99214 and 99213 are labeled “extreme outlier, far above typical national volume” on Medicare, and administration codes such as 96375 are also labeled “extreme outlier, far above typical national volume,” which together suggest the provider bills far above typical national volumes for both E/M and certain infusion/administration events.
Competitive standing is mixed by code: the provider ranks near the top nationally for some drug and biosimilar volumes (for example, J9145 ranks #3 of 14 nationally and J9047 ranks #4 of 36), but those specific code descriptors are still characterized as “typical, unremarkable volume” in the dataset. By contrast, Q5119 (rituximab-biosimilar ruxience) shows an “extreme outlier, far above typical national volume” label (rank #4 of 335), indicating notable dominance among peers for that biosimilar.
Operational footprint is consistent with a high-volume infusion clinic: large claim counts for key infusion drugs and administration events include 21.5K claims for J9145, 11.8K claims for J9047, 8.1K claims for J1568, 2.7K claims for 96375, and 993 claims for 96365. Those volumes, combined with the outlier labels on administration and visit codes, imply substantial repeated patient throughput and resource needs around infusion nursing, drug handling, and observation capacity.
The provider has established tenure with an NPI enumerated on 2005-10-03 (~21 years ago), indicating long-standing activity in the market; combined with the concentrated Medicare drug revenue and high-volume infusion coding, this suggests an entrenched hematology/oncology practice that would be a meaningful counterparty for Medicare-focused drug and infusion payment models.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
61 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9145 | Injection, daratumumab, 10 mg | 21,500 | $50 | $1M |
| J9047 | Injection, carfilzomib, 1 mg | 11,800 | $40 | $424.8K |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 8,060 | $30 | $266K |
| J0897 | Injection, denosumab, 1 mg | 13,860 | $20 | $249.5K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,740 | $90 | $159.7K |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 7,480 | $20 | $157.1K |
| J9312 | Injection, rituximab, 10 mg | 2,280 | $60 | $145.9K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,780 | $70 | $115.6K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 860 | $90 | $80.6K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 33,500 | $1 | $67K |
Showing 1–10 of 61
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 61 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
61 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9145 | 1 | 10 | 21,500 | $50 | $1M |
| J9312 | 3 | 10 | 2,000 | $60 | $129.8K |
| J9047 | 1 | 10 | 2,070 | $40 | $108.9K |
| J1568 | 1 | 10 | 2,190 | $30 | $96.9K |
| J0897 | 29 | 410 | 2,520 | $20 | $90.8K |
| Q5119 | 1 | 40 | 1,970 | $20 | $50.6K |
| J0881 | 7 | 70 | 11,600 | $1 | $38.2K |
| J2506 | 16 | 70 | 320 | $80 | $32.9K |
| J9217 | 63 | 160 | 140 | $130 | $21.1K |
| Q5106 | 16 | 40 | 2,700 | $10 | $20.5K |
Showing 1–10 of 61
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
13 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 2,020 | $20 | $46.4K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 2,590 | $10 | $15.5K |
| 99232 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making or… | 220 | $30 | $5.5K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 610 | $1 | $2.4K |
| 96375 | Following the administration of a drug or other substance via intravenous, or IV, push, the provider sequentially infuses a different medication or medications, also via IV push. He administers the… | 470 | $1 | $1.4K |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | 140 | $1 | $410 |
| 96365 | The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease. | 280 | $1 | $280 |
| J1756 | Injection, iron sucrose, 1 mg | 50 | $10 | $230 |
| J1750 | Injection, iron dextran, 50 mg | 20 | $10 | $110 |
| 96372 | A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician… | 50 | $1 | $50 |
Showing 1–10 of 13
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
13 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,714 | 14,680 | 300 | $50 | $48.7K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 424 | 830 | 700 | $1 | $47.5K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,549 | 14,190 | 280 | $20 | $38.9K |
| 99232 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making or… | 2,336 | 4,800 | 210 | $30 | $29.3K |
| 96365 | The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease. | 20 | 80 | 150 | $40 | $29.3K |
| 96375 | Following the administration of a drug or other substance via intravenous, or IV, push, the provider sequentially infuses a different medication or medications, also via IV push. He administers the… | 23 | 80 | 120 | $20 | $17.1K |
| J1750 | Injection, iron dextran, 50 mg | 4 | 10 | 20 | $110 | $8.4K |
| 96372 | A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician… | 585 | 900 | 120 | $10 | $3.5K |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 567 | 1,510 | 110 | $1 | $3.5K |
| J1756 | Injection, iron sucrose, 1 mg | 14 | 20 | 60 | $10 | $2.7K |
Showing 1–10 of 13
Other providers in the same ZIP code as Syed Zahir, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Ecker Center For Behavioral Health | IL | Mental Health Clinic/Center (Including Community Mental Health Center) | $0 | $20M |
| A-tec Ambulance Service Inc | IL | Land Ambulance | $3.4M | $8.3M |
| Kenneth Laferle | IL | Audiologist | $8K | $5.8M |
| Vna Health Care | IL | Federally Qualified Health Center (FQHC) | $0 | $5.1M |
| Cranial Technologies, Inc. | IL | Prosthetic/Orthotic Supplier | $0 | $4M |
| Veerpal Singh | IL | Hematology & Oncology Physician | $3.4M | $67.3K |
| Suleman Bangash | IL | Dermatology Physician | $3M | $5.2K |
| Rashmi Kapur | IL | Ophthalmology Physician | $1.6M | $1.1M |
| Rehan Hussain | IL | Ophthalmology Physician | $2.2M | $236K |
| Nexgen Labs Inc | IL | Clinical Medical Laboratory | $204.3K | $2.1M |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.